Etomidate

Chang, Zui L.; Martin, Joseph B.

doi:10.1016/s0099-5428(08)60167-7

Cited by 1 publication

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, except for (S)-etomidate all other impurities are listed as racemates although the published synthetic procedures involve either pathways starting from chiral precursors, or include a resolution step via diastereomer crystallization at the stage of the etomidate acid [19][20][21]. The isopropyl ester could not be included in the current study as the compound is not commercially available.…”

Section: Resultsmentioning

confidence: 99%

“…Etomidate and metomidate are weak bases, a pK a value of 4.2 has been reported for etomidate [20]. Etomidate acid on the other hand is an amphoteric compound with an estimated pK a of the carboxylic acid function of 2.3 [22].…”

Section: Methods Developmentmentioning

confidence: 99%

“…3D), injecting high concentrations of etomidate resulted in comigration of (S)-metomidate and etomidate. However, as (S)-metomidate is a very unlikely impurity based on the reported synthetic procedures [19][20][21], the comigration does not represent a significant drawback of the method.…”

Section: Methods Optimizationmentioning

confidence: 99%

See 2 more Smart Citations

Development and validation of a robust capillary electrophoresis method for impurity profiling of etomidate including the determination of chiral purity using a dual cyclodextrin system

2006

View full text Add to dashboard Cite

An enantioselective CE assay for the simultaneous determination of the enantiomeric purity and of related substances of etomidate has been developed and validated using a binary chiral selector system employing 30 mg/mL beta-CD and 4.6 mg/mL sulfated-beta-CD in a 150 mM potassium phosphate buffer, pH 2.1. The method was validated with respect to specificity, range, linearity, LOQ and LOD, precision and accuracy. The assay allowed the detection and determination of related substances including (S)-etomidate at the 0.05% w/w level, the reporting threshold as defined by the International Conference on Harmonisation guidelines as well as the European Pharmacopoeia. Robustness testing was carried out by an "Augmented Plackett-Burman" design. Quantitation of the compounds was performed by calibration graphs with respect to lidocaine hydrochloride as internal standard and by peak area normalization, the procedure usually applied by pharmacopoeias. Although data obtained from the calibration graphs constructed with the aid of the internal standard were more accurate based on compound recovery, peak area normalization may also be used without significant loss of accuracy and precision.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methods Developmentmentioning

confidence: 99%